Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Leas

Orthopaedic Surgery of the Spine Concord, NC Medical Doctor

NPI 1598027252 CMS profile 949458

110 Lake Concord Rd Ne, Concord, NC 28025

Open in the dashboard

General payments

$42,254

194 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Leas of Concord, NC is reported in the CMS Open Payments database as having received $42,254 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,117 36
2024 General $3,832 36
2023 General $2,195 30
2022 General $7,969 15
2021 General $2,324 14
2020 General $6,510 22
2019 General $4,309 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Leas
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Daniel Leas were reported at $15,117. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Daniel Leas Orthopaedic Surgery of the Spine median Middle half National median
2019 $4,309 $2,106 $337–$18,608 $163
2020 $6,510 $1,213 $156–$15,082 $114
2021 $2,324 $1,834 $271–$15,617 $132
2022 $7,969 $2,015 $320–$17,036 $149
2023 $2,195 $1,925 $336–$14,599 $160
2024 $3,832 $2,110 $341–$12,483 $164
2025 $15,117 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $15,993 66 payments
  2. restor3d, inc. $10,735 3 payments
  3. Medical Device Business Services, Inc. $4,020 12 payments
  4. NuVasive, Inc. $3,973 23 payments
  5. Medtronic USA, Inc. $3,369 31 payments
  6. Boston Scientific Corporation $1,687 36 payments
  7. Globus Medical, Inc. $1,206 4 payments
  8. DePuy Synthes Products, Inc. $540 1 payment
  9. DePuy Synthes Sales Inc. $484 11 payments
  10. Spine Wave, Inc. $102 1 payment
  11. Other $146 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $24,010 6 payments
  2. Travel and Lodging $11,033 45 payments
  3. Food and Beverage $7,152 142 payments
  4. Education $59 1 payment
Products named General payments · program years 2019–2025
  1. MIDAS REX $11,177 9 payments
  2. TLIF $1,984 9 payments
  3. STEALTHSTATION S8 PLATFORM $1,424 12 payments
  4. CD HORIZON SPINAL SYSTEM $1,423 14 payments
  5. XLIF $1,183 7 payments
  6. WaveWriter Alpha Prime 16 $1,130 26 payments
  7. ELSA ATP $1,077 2 payments
  8. EXPEDIUM $877 11 payments
  9. PIVOX Oblique Lateral Spinal System $734 5 payments
  10. MAZOR X SYSTEM $413 13 payments
  11. Other $3,836 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

227

Median for Orthopedic Surgery: 203

Drug cost

$2,019

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 65 $986
Gabapentin Generic 46 $473
Tizanidine Hcl Generic 35 $226
Methylprednisolone Generic 39 $223
Meloxicam Generic 42 $111

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$155,156

Medicare's payments for the services billed

Medicare patients

203

Average age 73

Services billed

718

109 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 37%
Diabetes 35%
Ischemic heart disease 30%
Chronic kidney disease 26%
Osteoporosis 26%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record